Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, PMID: 25008258
Gemtuzumab ozogamicin in acute myeloid leukemia, PMID: 28607471
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia, PMID: 29787320
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial, PMID: 30076173
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future, PMID: 32955828
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment, PMID: 32781546
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia, PMID: 33059764
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers, PMID: 31462392
Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab, PMID: 28003274
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group, PMID: 30093401
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study, PMID: 31851556
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, PMID: 22482940
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia, PMID: 31880804
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial, PMID: 33367545
Gemtuzumab ozogamicin, PMID: 11511025
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial, PMID: 26811524
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531, PMID: 25092781
Acute myeloid leukaemia, PMID: 30078459
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin, PMID: 32988266
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, PMID: 23591789
Acute myeloid leukemia: 2021 update on risk-stratification and management, PMID: 32833263
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial, PMID: 21172891
Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come, PMID: 30598494
[Intraperitoneal perfusion of gemtuzumab-ozogamicin combined with allogeneic hematopoietic stem cell transplantation in intestinal solitary myeloid sarcoma: a case report and literature review], PMID: 32942825
Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia, PMID: 26646091
[Gemtuzumab ozogamicin for treatment of acute myeloid leukemia], PMID: 24557850
Gemtuzumab ozogamicin in acute myeloid leukemia revisited, PMID: 24865510
How I diagnose and treat NPM1-mutated AML, PMID: 33171486
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia, PMID: 12503209
Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia, PMID: 21810061
[Gemtuzumab ozogamicin and targeted cancer therapy], PMID: 15226619
Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia, PMID: 16266206
Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome, PMID: 30797942
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia, PMID: 18352855
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin, PMID: 16562371
Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience, PMID: 33219461
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia, PMID: 17942233
AML: New Drugs but New Challenges, PMID: 32151586
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia, PMID: 12162910
[Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia], PMID: 17633093
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis, PMID: 24033280
New drugs creating new challenges in acute myeloid leukemia, PMID: 30861214
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia, PMID: 14601078
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy, PMID: 21142804
Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials, PMID: 18063879
The optimal dosing of gemtuzumab ozagamicin: where to go from here?, PMID: 27252508
[Gemtuzumab ozogamicin combined chemotherapy for elderly patients with acute myeloid leukemia], PMID: 24881915
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia, PMID: 30039981
Gemtuzumab Ozogamicin Makes a Comeback, PMID: 28931515
Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report, PMID: 32871966
Pharmacovigilance insights into antibody-drug conjugates: a multi-database analysis of adverse events in leukemia treatment., PMID:40522479
Synchronous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma: A Case Report and Literature Review., PMID:40486382
Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation., PMID:40437770
Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy., PMID:40425554
A platform for SpyCatcher conjugation to native antibodies., PMID:40386161
Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase® Disproportionality Analysis., PMID:40272201
CD33-D2 isoform characterization for advancement of its therapeutic potential., PMID:40272002
Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia., PMID:40270973
US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines., PMID:40178688
Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531., PMID:40150760
Recent advances of CAR-T cells in acute myeloid leukemia., PMID:40144774
Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes From the HERO Consortium., PMID:40135741
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groups., PMID:39993233
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trials., PMID:39976269
New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers., PMID:39941372
Utility of ursodiol prophylaxis against sinusoidal obstruction syndrome (SOS)/ veno-occlusive disease (VOD) in acute leukemia patients receiving gemtuzumab-ozogamicin (GO) or inotuzumab-ozogamicin (InO)., PMID:39819278
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML., PMID:39816531
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis., PMID:39742259
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study., PMID:39721590
Treatment of a Pediatric Patient with Core Binding Factor Acute Myeloid Leukemia Post-Cytotoxic Therapy With Cytarabine, Daunorubicin, and Gemtuzumab Followed by Stem Cell Transplantation., PMID:39702892
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial., PMID:39689718
Acute myeloid leukemia management and research in 2025., PMID:39656142
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia., PMID:39601208
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions., PMID:39587643
The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review., PMID:39586174
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia., PMID:39584789
Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice., PMID:39475662
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS., PMID:39454204
In vitro and in vivo expansion of CD33/HBG promoter-edited HSPCs with Mylotarg., PMID:39429723
Safety considerations for drugs newly approved for treating acute myeloid leukemia., PMID:39364854
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia., PMID:39335185
Current status and research directions in acute myeloid leukemia., PMID:39300079
Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia., PMID:39235263
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
Successful Treatment of Very Severe Sinusoidal Obstruction Syndrome After Gemtuzumab Ozogamicin With Transjugular Intrahepatic Portosystemic Shunt, Defibrotide, and High-Dose Corticosteroids: A Case Report., PMID:39185292
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia., PMID:39157611
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT., PMID:39095548
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia., PMID:39062189
Cardiotoxicity in Acute Myeloid Leukemia in Adults: A Scoping Study., PMID:39001536
Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome., PMID:38965693
High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia., PMID:38963637
CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity., PMID:38853211
Immunotherapeutic targeting of surfaceome heterogeneity in AML., PMID:38838225
Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib., PMID:38813731
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies., PMID:38783125
Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database., PMID:38766629
Advancements and Challenges in the Treatment of AML., PMID:38662975
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients., PMID:38662362
For research use only. Not for human or drug use.
